<SEC-DOCUMENT>0001437749-20-019576.txt : 20200910
<SEC-HEADER>0001437749-20-019576.hdr.sgml : 20200910
<ACCEPTANCE-DATETIME>20200910163934
ACCESSION NUMBER:		0001437749-20-019576
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200910
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200910
DATE AS OF CHANGE:		20200910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		201169055

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20200907_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head>
	<title>dffn20200907_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 9/10/2020 8:05:12 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>UNITED STATES</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">________________</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>FORM 8-K</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>CURRENT REPORT</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>the Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">__________________</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (Date of earliest event reported):&nbsp;</b><b>September 10, 2020</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">___________________</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:33.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align:top;width:33.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>000-24477</b></p>
			</td>
			<td style="vertical-align:top;width:33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">incorporation)</p>
			</td>
			<td style="vertical-align:top;width:33.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number)</p>
			</td>
			<td style="vertical-align:top;width:33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:42.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>1317 Carlton Avenue, Suite 200</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Charlottesville, Virginia</b></p>
			</td>
			<td style="vertical-align:top;width:49.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>22902</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:top;width:49.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(434) 220-0718</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Not applicable</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed since last report)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:37.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Title of each class</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:20.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Trading Symbol(s)</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:41.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:37.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:20.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">DFFN</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:41.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Nasdaq Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b>&#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</b>&#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item&nbsp;</b><b>8</b><b>.0</b><b>1</b><b>. </b><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><b>Other Events.</b></p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On September 10, 2020, Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing the dosing of the first patients in the Company&#8217;s open-label Phase 1b lead-in trial of its novel, oxygen-enhancing therapeutic, trans sodium crocetinate. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item&nbsp;9.01. Financial Statements and Exhibits.</b></p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)&nbsp;Exhibits.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">99.1</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_203491.htm" style="-sec-extract:exhibit;">Press Release issued September 10, 2020</a></p>
			</td>
		</tr>

</table>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURES</b></p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dated: September 10, 2020</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Diffusion Pharmaceuticals, Inc.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:Times New Roman;font-size:1pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ William Hornung</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:Times New Roman;font-size:1pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:1pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: William Hornung</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:Times New Roman;font-size:1pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:1pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title: Chief Financial Officer</p>
			</td>
		</tr>

</table>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_203491.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_203491.htm</title>

	<!-- Generated by ThunderDome Portal - 9/10/2020 8:04:11 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="" src="logo02.gif"></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Diffusion Pharmaceuticals Doses First</b><b> Two</b><b> Patient</b><b>s</b><b> with TSC in COVID-19 Clinical Trial</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>Twenty-four patient Phase 1b safety and tolerability study initiated in Romania</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>CHARLOTTESVILLE, Va. (</b><b>September </b><b>10</b><b>,</b><b> 2020</b><b>) &#8211; Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)</b> (&#8220;Diffusion&#8221; or the &#8220;Company&#8221;) today announced dosing of the first two patients in the Company&#8217;s open-label Phase 1b lead-in trial of its novel, oxygen-enhancing therapeutic, trans sodium crocetinate (&#8220;TSC&#8221;), in 24 hospitalized COVID-19 patients. In addition to evaluating the safety and tolerability of TSC, this trial will collect preliminary data on TSC&#8217;s effects on arterial blood oxygenation. The Company believes these pharmacodynamic data will provide proof of concept for TSC in hypoxemic patients, and these data will be used to guide design of the planned follow-on efficacy study.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Phase 1b study is being conducted at the Romanian National Institute of Infectious Diseases. The planned follow-on efficacy trial will be a randomized, placebo-controlled safety and efficacy study of TSC in hospitalized COVID-19 patients that will be conducted in the United States and Europe after consultation with, and approval from, local regulatory authorities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#8220;Dosing TSC in oxygen-deprived, hospitalized COVID-19 patients is an important milestone for Diffusion.&#8221; said Robert Cobuzzi, chief executive officer of Diffusion. &#8220;We anticipate learning a lot about TSC&#8217;s effects on blood oxygen levels in COVID-19 patients, and we&#8217;re excited about the potential to incorporate the knowledge gained from this study into the broader TSC development program.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>About TSC and COVID-19</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Patients with COVID-19 respiratory tract infections often present with significantly impaired oxygen levels. Diffusion and its affiliated researchers believe the oxygen-enhancing mechanism of action of TSC could benefit such patients. Preclinical data indicate TSC increases oxygen availability and provides a functional benefit in animal models of acute lung injury and hemorrhagic shock. Clinical data from more than 150 patients receiving TSC for other indications demonstrate that the drug has an acceptable safety profile in both healthy and critically ill patients.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body&#8217;s ability to deliver oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions. Diffusion&#8217;s lead drug, TSC, was originally developed in conjunction with the United States (&#8220;U.S.&#8221;) Office of Naval Research, which was seeking a way to treat multiple organ failure and its resulting mortality caused by low oxygen levels from blood loss on the battlefield. Evolutions in research have led to Diffusion&#8217;s focus today on addressing some of medicine&#8217;s most intractable and difficult-to-treat diseases, including multiple organ failure from respiratory distress, stroke and glioblastoma multiforme (&#8220;GBM&#8221;) brain cancer. In each of these diseases, lack of available oxygen presents a significant obstacle for medical providers and is the target for TSC&#8217;s novel mechanism. The Company is currently partnering with U.S. and European institutions on an expedited research program to develop TSC as a treatment for the low oxygen levels and associated multiple organ failure in COVID-19 patients.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Preclinical data support the potential for TSC as a treatment for other conditions where low oxygen availability plays an important role, such as myocardial infarction, peripheral artery disease and neurodegenerative conditions such as Alzheimer&#8217;s and Parkinson&#8217;s disease. In addition to the development of TSC, RES-529, the Company&#8217;s PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion is headquartered in Charlottesville, Virginia &#8211; a hub of advancement in the life science and biopharmaceutical industries.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Forward-Looking Statements </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Diffusion&#8217;s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: the timing of the enrolment and completion of the Phase 1b study, the pharmacodynamic data providing proof of concept for TSC in hypoxemic patients, and the use of these data to guide design of the planned follow-on efficacy study; the uncertainty as to whether the protocol for the planned United States and European follow-on efficacy study referenced above will be ultimately acceptable to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and appropriate European regulators, that the FDA or European regulators will not require significant changes that might take significant time to implement, if at all, that any such required changes will be financially feasible or that administrative or other delays may arise; the uncertainty as to whether and when the FDA or European regulators might provide any additional guidance with respect to our study protocol or when the program might be able to commence, if at all; the uncertainty that as of yet the FDA has not approved a trial evaluating TSC for the treatment of ARDS, or if approved, such a trial may entail significant additional time, effort and expense, particularly in light of the difficulty of doing business during the COVID-19 pandemic; Diffusion&#8217;s ability to maintain its Nasdaq listing, market conditions, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; general business and economic conditions; the sufficiency of the company&#8217;s cash, the company's need for and ability to obtain additional financing or partnering arrangements; and the various risk factors (many of which are beyond Diffusion&#8217;s control) as described under the heading &#8220;Risk Factors&#8221; in Diffusion&#8217;s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Contacts:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Robert Cobuzzi, Ph.D., CEO</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion Pharmaceuticals Inc.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(434) 220-0718</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">rcobuzzi@diffusionpharma.com</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">LHA Investor Relations</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Kim Sutton Golodetz</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(212) 838-3777</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">kgolodetz@lhai.com&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Media Contact:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Jeffrey Freedman</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">RooneyPartners</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">646-432-0191</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">jfreedman@rooneyco.com</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 100%; text-align: center;"># # #</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo02.gif
<TEXT>
begin 644 logo02.gif
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MJWGCZJ#ZZJ@WN4,.D9"*Q OZMB"-0$11PT+MI 2PWBSNI+!C#<?EL((JO@>
MRN936 AK (M @$ "%QCP]P4+'$" !XW,,6M!KEQA@P\V3'(%#/[QZ$,*0S!6
MT>4L"L1$Z !:<8M GX<> NG#.)*#>2-H$@X@@0,<W*!7YN&!#FY@*5(=(08!
M=,'MNA0 W9GG!:,8R#?*TP,:= $3F)C'"@J4E.69YPUN"  > @ "#1#@ AA(
M0 ,T  $&)& !"R" !%9Q!Y;ACBAAHH,\_Q[% P;"( <S<$346##!]\FH!]XJ
MB(HZ485>]0<-^ /=#FY0KCCTHAHW^$\-NL +7YC1$\Q08 ]JH 4S]J(P1RA!
M@ES H(%8L <NR&  X@"$&O0@!N18%"VF02J!F+ '*$15 #HP/0P<P $4X$P'
M,I" &"+@ RKTGE+Z4 <>$H4.)'@4@'+ #5]0@QZ.,(\+Y!,<B,!O10&@A16L
MZ ,L!B!_HB.=0/QP QWT8 99*$@MZ!<#UQ DCG.LHT#NF$>!\*(>QH+!%Q)R
M2!=8* !8D-X%+L" #ZRG#@'@  *VB0 )S,E[+UK9MKP02O/< U>K.(8-?&D#
M>*C%B3.*8OP"</^&64;(![K(8NAP4*ZDA**7OR1"0=! S"-T)@#(] $="<),
M/;X"'G[L 17,,0I7"(053SDD(8H6  HTH)(&>$!A+,$91&1@ 3%LP")ZV(<U
ML0F=>Y1'*G,@CU=()0[SP$'H=K"+5C[DE;A+BAIRX$L9:"$ZMV22Z,HED(/Z
M<@9#*(@NB(F$@D1THG9D@2KU& !N) )U,8@!/%!!LX&(E*2,7, %#J !<*Z"
M38MPP %BB %$! "<+((#400!B$?%P!Q=$0,,>N $'13U6@Q!*@4#L(W-M6":
M IWJ0*SZRZP29*O&BD%7CUD"*X%UF6+%8^^0T@IQ)"*C/J@!"KI@"[?_;HX0
MU_S  7"(  YLJPYL @$$=IN #/@U (B8  <XT(%#2(6PAJ5$08JPV,86%9]0
M_-F*-A$$&IBG!=C!GU0)NEF$8E6K7"U()F)@)=L19!JI;>:8L,D&>;@ !O_A
M@0JTL*A#WN.:'=CM A 0@34]I1$/N&%Q_<H! 53@P0AX  6Z!,KH3K>ZCK7(
M*U^$BBKU( =5*)AX!TK5TIG7LZ])+T'  (, LJ 469%&?#.X%24T80RI;)(+
MF&'(S5E3(!]@ /92NJ8]@',1&<">#!<!!PDH0 ,1&*X%((";. SQC](E"'49
MFV'LMD"[ [G&(WQIJVT0!!-2A42).7O>ST+S_X^C'8@U7*#*-IP9@B/ H*$*
MDHT8S$@%N#ID"RQTAT,\P  Q]:LE>AAD[-$5"W! !";AT @(%$  $[:RA0EB
M!PQ?ER*U<D$JQA2'73S#'*HID0N X(4[AT[-Y;TJB@6BBS>+MB#.6 &/;A")
M9&AB%JI@A \BN%I6,*.V QF&N'J0@D#[6 X"V8,$+"#7 T0 1(8N  8&W($Y
M<!(.J0HG ;H9 "]<.099'DBGN?SIB=1J!_/(@A"X( DJQ&!'/E@!/7I1$#2_
M>LTGUJJMX^S,!9H'!SG8 @EB,&8>N< 94.&"%<9!#5%$8PM"U4$,BM%C54*[
M2XAHP &PAP (=& "#_\8.0:F#(4[L-3;*_0  62:TTVKV],:QN][ A0#&OAG
M!%-C@3D>2Q!R@,X)7"ROL6:@4(*@P=9D,$@X.*A &>0@!D"@AR]=$ V!["(2
M5+AO<ORXOC& 2*3.FP,<.J   1N  7[#P 4LT( )SZ$.?3!5 (*LPZ0(0GQ8
M+LBZK6M4ARA#'\F900UH((/D:$T'E.CZG@5R-!@PAVD"4<,*6@"#1%2B(+NP
M/ Q.@(ZN!& )74!!#?0E@Q148A=:2,0+]F&-S,M^!OW1 0U<L )*+$$JJN '
M#%Y@B#]D4I(/\)L!+I" !"!  1"@0*KPSM*2-H  #TA9  91!10PC@M>17S_
M"UJ0AL(O)"E^R$(YR'".+OR "$<XPA?6P(2!C&DKJ1#"&(Q !EX,Y!-(8 1B
M0 EP<Q;[-P9"H I;D11F\ W=]0@_T :_APU9, ;G &.K$ MK$ ;I< ,V8 -
M, ;2L"@"(0U$, 9CD 77$ !PP I&!CT3  $.(  "\  >T %8P()(L0<"00$.
M0 "0]%>KL GBD 0(:&?SM0K:4(%&8 3W UD/ 0=>4 9<DB(M\A$+.!!Q  S
M %5B@A6LT N_\ M9TAEU$BM[L >QHDB+0 $4T @#D8;5LBTF10 0H'V&\X54
M\85K,1.L4(4$<2H?T #:M@$GQP$4T$-]N(@&@0@"_U  E50 !& ! S !J/(]
MC&@5%"  &=")GJ@ EH@2"Q@M/!$5G\(1?0 "B+"*K+B*C4 MK+(22/$+R-83
M(,6'#+$*M/ +"L$I4H0J=7 J)7$&6W %\M .TQ =K, "X. 3\S40F@ .O?,0
M;8 /"]$+?. ':V(J1*%.?>!#(Q$, ' .IQ &^[ .('4/EY"+]J<5IX@Y61@1
MUC - B$+41 >DU=XW3 %#Q4<Q0  >:!( _&-?P6.(@$,   D 6 , - , 1 #
M)-6/[\@5+1,6IMB.!7&+4K$5CH"/?YB/1I44W7 /[B@0Q   R( 02!&+$LD1
M" EQ D$#S4@%WR -\Z %C_\%"];0!?"0"HP1#M'@!^K@"M. "KE "?&00=4P
M#^CP6+2 #3_P#MG %;YP"4#P#O08 ,6@#NW0!HQ!#MB1%&W0#9KP#OHP!?,P
ME5F *W%0#>S@#F2@";!@"CRI#2 RDEY7#C_P!94S$">9DL&0"K80!O, #AZ5
M%+IP">X0#V'Y$0@Y%P%PD@YI!?C !4D "?9@!@&0!NC@#=V #YE0&/3P#O10
M#IK0#3[P V00#U+P#?&0!+#C4<% "=U@5F"0%,7 #^QP#>$PE:5P#]]P#5;
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M#ZQ@!E>@#^Q2"5%P# %@!KZ@">OP"+S8"DQ0&.#0D+5P"0"099$0#[&P"K(
M -.$#  @#K@A#*V@#E70"K 0#U$0'=W  E%;+K2P F- $&H  ,D0 )%JKLWP
MH % #OS 8X.0"ZT #MS@$48*DTE" R1E!OL@7<,0 _30#DE !0T*!#, (MK
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87,56?,58G,5:O,5<W,5>_,5@/!,! 0 [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
